Stocktoria
Absci Corp ABSI
Absci Corp (ABSI) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.8M at a -4113.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.586 |
| Retained earnings / assets | -2.889 |
| EBIT / assets | -0.556 |
| Equity / liabilities | 7.056 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ABSI | Absci Corp | 2/9 | -1.9 | — | — |
| ISPC | iSpecimen Inc. | 3/9 | — | — | — |
| ONMD | OneMedNet Corp | 5/9 | — | — | — |
| VSBC | VITASPRING BIOMEDICAL CO. LTD. | 4/9 | — | — | — |
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
FAQ
Is ABSI financially healthy?
Absci Corp's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ABSI pay a dividend?
No, Absci Corp does not currently pay a dividend.
How profitable is ABSI?
In FY2025, Absci Corp had a net margin of -4113.7% and a return on equity of -60.8%.
What is the analyst price target for ABSI?
The average Wall-Street price target for Absci Corp is $12.40, about 30.5% above the recent price, from 10 analysts (consensus: strong buy).
Is ABSI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Absci Corp: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.